- Report
- May 2026
- 185 Pages
Global
From €4098EUR$4,500USD£3,534GBP
- Report
- June 2026
- 182 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- October 2025
- 598 Pages
Global
From €4370EUR$4,799USD£3,769GBP
- Report
- June 2026
- 184 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- January 2026
- 191 Pages
Global
From €3228EUR$3,545USD£2,784GBP
€3587EUR$3,939USD£3,093GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- June 2026
- 377 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 419 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 188 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- November 2025
- 200 Pages
Global
From €7239EUR$7,950USD£6,243GBP
- Report
- April 2026
- 160 Pages
Global
From €3779EUR$4,150USD£3,259GBP
- Report
- September 2025
- 150 Pages
Global
From €4416EUR$4,850USD£3,809GBP
- Report
- February 2025
- 315 Pages
Global
From €4370EUR$4,799USD£3,769GBP
- Report
- January 2025
- 363 Pages
Global
From €4370EUR$4,799USD£3,769GBP
- Report
- March 2025
- 1048 Pages
Global
From €4370EUR$4,799USD£3,769GBP
- Report
- November 2023
- 90 Pages
France
From €3187EUR$3,500USD£2,749GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4553EUR$5,000USD£3,927GBP

Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma.
Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more